Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Solid Tumors, KRAS Mutation”

156 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 156 results

Early research (Phase 1)Looking for participantsNCT06659341
What this trial is testing

A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation

Who this might be right for
Advanced Solid Tumors Harboring KRAS G12C Mutation
Bayer 104
Testing effectiveness (Phase 2)Active Not RecruitingNCT04699188
What this trial is testing

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Who this might be right for
KRAS G12C Mutant Solid TumorsCarcinoma, Non-Small-Cell LungCarcinoma, Colorectal+7 more
Novartis Pharmaceuticals 344
Early research (Phase 1)Looking for participantsNCT06179160
What this trial is testing

Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Who this might be right for
Solid Tumors
Incyte Corporation 710
Testing effectiveness (Phase 2)Looking for participantsNCT06667544
What this trial is testing

RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation

Who this might be right for
KRAS G12D Mutation
Ranok Therapeutics (Hangzhou) Co., Ltd. 152
Early research (Phase 1)Looking for participantsNCT06227377
What this trial is testing

QTX3034 in Patients With KRAS G12D Mutation

Who this might be right for
Solid Tumors
Quanta Therapeutics 250
Early research (Phase 1)Active Not RecruitingNCT06428500
What this trial is testing

QTX3046 in Patients With KRAS G12D Mutations

Who this might be right for
Advanced Solid Tumor
Quanta Therapeutics 240
Testing effectiveness (Phase 2)UnknownNCT06237413
What this trial is testing

ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours

Who this might be right for
Solid TumorKRAS Mutation-Related Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 110
Early research (Phase 1)Looking for participantsNCT07134998
What this trial is testing

Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations

Who this might be right for
Advanced KRAS G12D Mutant Solid Tumors
Jiangsu HengRui Medicine Co., Ltd. 153
Testing effectiveness (Phase 2)Active Not RecruitingNCT03600883
What this trial is testing

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Who this might be right for
KRAS p.G12C Mutant Advanced Solid Tumors
Amgen 713
Early research (Phase 1)Study completedNCT04330664
What this trial is testing

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

Who this might be right for
Advanced CancerMetastatic CancerMalignant Neoplastic Disease
Mirati Therapeutics Inc. 86
Not applicableNot Yet RecruitingNCT07396090
What this trial is testing

Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors

Who this might be right for
Advanced Solid Tumor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 13
Testing effectiveness (Phase 2)Looking for participantsNCT07148128
What this trial is testing

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

Who this might be right for
Advanced or Metastatic KRAS-mutant Tumor in Pancreatic AdenocarcinomaAdvanced or Metastatic KRAS-mutant Tumor in Colorectal CancerAdvanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer+2 more
Auricula Biosciences Inc.
Testing effectiveness (Phase 2)Active Not RecruitingNCT05009329
What this trial is testing

JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China

Who this might be right for
NSCLCSolid Tumor
Allist Pharmaceuticals, Inc. 315
Early research (Phase 1)Not Yet RecruitingNCT06545201
What this trial is testing

RE001 T Cell Injection for the Treatment of KRAS G12V Mutated Solid Tumors

Who this might be right for
KRAS G12VT Cell Therapy
Henan Cancer Hospital 30
Early research (Phase 1)Looking for participantsNCT06447662
What this trial is testing

Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Who this might be right for
Carcinoma, Pancreatic DuctalColorectal NeoplasmsCarcinoma, Non-Small-Cell Lung
Pfizer 330
Early research (Phase 1)Study completedNCT04006301
What this trial is testing

First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation

Who this might be right for
NeoplasmsAdvanced Solid TumorsNon-small Cell Lung Cancer+1 more
Janssen Research & Development, LLC 10
Early research (Phase 1)Study completedNCT03101839
What this trial is testing

Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours

Who this might be right for
Non-Small Cell Lung CancerAdvanced Solid Tumours
AstraZeneca 28
Early research (Phase 1)Active Not RecruitingNCT07474168
What this trial is testing

T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

Who this might be right for
Tumor
Zhejiang University 9
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06435455
What this trial is testing

GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation
Suzhou Genhouse Bio Co., Ltd. 126
Early research (Phase 1)Looking for participantsNCT06619587
What this trial is testing

Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Genentech, Inc. 410
Load More Results
110